Zhang Wenchao, Liu Zhongyue, Yang Zhimin, Feng Chengyao, Zhou Xiaowen, Tu Chao, Li Zhihong
Department of Orthopaedics, The Second Xiangya Hospital, Central South University, Changsha, China.
Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital, Central South University, Changsha, China.
Front Oncol. 2021 Dec 15;11:781386. doi: 10.3389/fonc.2021.781386. eCollection 2021.
Previous studies have revealed the critical role of methylene tetrahydrofolate reductase (MTHFR) polymorphisms in response to high-dose methotrexate (MTX)-induced toxicity in osteosarcoma patients. However, the conclusions remain controversial. In this setting, we performed a meta-analysis to determine their association more precisely.
Eligible studies were searched and screened in PubMed, Web of Science, Cochrane Library, Clinical-Trials.gov, Embase, and China National Knowledge Infrastructure (CNKI) following specific inclusion and exclusion criteria. The required information was retrieved and collected for subsequent meta-analysis. Association between MTHFR polymorphism and MTX toxicity was evaluated by odds ratios (ORs).
Seven studies containing 585 patients were enrolled and analyzed in this meta-analysis. Overall, the MTX related grade 3-4 liver toxicity was significantly associated with MTHFR rs1801133 allele (T C: OR=1.61, 95%CI=1.07-2.42, P=0.024), homozygote (TT CC: OR=2.11, 95%CI=1.06-4.21, P=0.011), and dominant genetic model (TT/TC CC: OR=3.15, 95%CI=1.30-7.60, P=0.035) in Asian population. Meanwhile, close associations between MTX mediated grade 3-4 mucositis and MTHFR rs1801133 polymorphism were identified in allele contrast (T C: OR=2.28, 95%CI=1.49-3.50, P<0.001), homozygote comparison (TT CC: OR=4.07, 95%CI=1.76-9.38, P=0.001), heterozygote comparison (TC CC: OR=2.55, 95%CI=1.20-5.42, P=0.015), recessive genetic model (TT TC/CC: OR=2.09, 95%CI=1.19-3.67, P=0.010), and dominant genetic model (TT/TC CC: OR=2.97, 95%CI=1.48-5.96, P=0.002). Additionally, kidney toxicity was corelated with the heterozygote comparison (TC CC: OR=2.63, 95%CI=1.31-5.29, P=0.007) of rs1801133 polymorphism.
The MTHFR rs1801133 polymorphism was significantly associated with severer liver toxicity induced by high-dose MTX treatment in the Asian population. In the meantime, patients with MTHFR rs1801133 polymorphism were predisposed to MTX- related mucositis.
先前的研究揭示了亚甲基四氢叶酸还原酶(MTHFR)基因多态性在骨肉瘤患者对大剂量甲氨蝶呤(MTX)诱导的毒性反应中的关键作用。然而,结论仍存在争议。在此背景下,我们进行了一项荟萃分析以更精确地确定它们之间的关联。
按照特定的纳入和排除标准,在PubMed、科学网、考克兰图书馆、临床试验.gov、Embase和中国知网(CNKI)中检索和筛选符合条件的研究。检索并收集所需信息以进行后续的荟萃分析。通过比值比(OR)评估MTHFR基因多态性与MTX毒性之间的关联。
本荟萃分析纳入并分析了7项研究,共585例患者。总体而言,在亚洲人群中,MTX相关的3 - 4级肝毒性与MTHFR rs1801133等位基因(T>C:OR = 1.61,95%CI = 1.07 - 2.42,P = 0.024)、纯合子(TT>CC:OR = 2.11,95%CI = 1.06 - 4.21,P = 0.011)以及显性遗传模型(TT/TC>CC:OR = 3.15,95%CI = 1.30 - 7.60,P = 0.035)显著相关。同时,在等位基因对比(T>C:OR = 2.28,95%CI = 1.49 - 3.50,P<0.001)、纯合子比较(TT>CC:OR = 4.07,95%CI = 1.76 - 9.38,P = 0.001)、杂合子比较(TC>CC:OR = 2.55,95%CI = 1.20 - 5.42,P = 0.015)、隐性遗传模型(TT>TC/CC:OR = 2.09,95%CI = 1.19 - 3.67,P = 0.010)以及显性遗传模型(TT/TC>CC:OR = 2.97,95%CI = 1.48 - 5.96,P = 0.002)中,均发现MTX介导的3 - 4级粘膜炎与MTHFR rs1801133基因多态性密切相关。此外,肾毒性与rs1801133基因多态性的杂合子比较(TC>CC:OR = 2.63,95%CI = 1.31 - 5.29,P = 0.007)相关。
MTHFR rs1801133基因多态性与亚洲人群中高剂量MTX治疗诱导的更严重肝毒性显著相关。同时,具有MTHFR rs1801133基因多态性的患者易发生MTX相关的粘膜炎。